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DNA damage is overcome by TRIP13
overexpression during cisplatin
nephrotoxicity
Taketsugu Hama,1 Prashanth K.B. Nagesh,1,2 Pallabita Chowdhury,1 Bob M. Moore II,1
Murali M. Yallapu,1,2 Kevin R. Regner,3 and Frank Park1
Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center,

1

Memphis, Tennessee, USA. 2Department of Immunology and Microbiology, School of Medicine, University of Texas Rio
Grande Valley, McAllen, Texas, USA. 3Division of Nephrology, Department of Medicine, Medical College of Wisconsin,
Milwaukee, Wisconsin, USA.

Cisplatin is a commonly used chemotherapeutic agent to treat a wide array of cancers that
is frequently associated with toxic injury to the kidney due to oxidative DNA damage and
perturbations in cell cycle progression leading to cell death. In this study, we investigated
whether thyroid receptor interacting protein 13 (TRIP13) plays a central role in the protection of
the tubular epithelia following cisplatin treatment by circumventing DNA damage. Following
cisplatin treatment, double-stranded DNA repair pathways were inhibited using selective
blockers to proteins involved in either homologous recombination or non-homologous end
joining. This led to increased blood markers of acute kidney injury (AKI) (creatinine and
neutrophil gelatinase–associated lipocalin), tubular damage, activation of DNA damage marker
(γ-H2AX), elevated appearance of G2/M blockade (phosphorylated histone H3 Ser10 and cyclin
B1), and apoptosis (cleaved caspase-3). Conditional proximal tubule–expressing Trip13 mice
were observed to be virtually protected from the cisplatin nephrotoxicity by restoring most of
the pathological phenotypes back toward normal conditions. Our findings suggest that TRIP13
could circumvent DNA damage in the proximal tubules during cisplatin injury and that TRIP13
may constitute a new therapeutic target in protecting the kidney from nephrotoxicants and
reduce outcomes leading to AKI.
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Acute kidney injury (AKI) is a major complication in nearly one-third of all cancer patients treated with
cisplatin, a common chemotherapeutic drug used for a variety of human cancers (1–3). The development
of nephrotoxicity is attributed to the rapid accumulation of cisplatin by active transport into renal tubular
epithelial cells, particularly in the S3 segment of the proximal tubules (4, 5). The accumulation of cisplatin
causes DNA cross-linking and, in some cases, more lethal physical breaks of the DNA (1, 6–10). These types
of damage to the genomic DNA play a critical role in the phenotypic changes exerted on tubular epithelial
cells and any subsequent loss of renal function (11, 12). To preserve normal function of the cells, checkpoint
systems have evolved to maintain genome stability by activating surveillance systems to ensure that damaged
DNA from previous cell cycle phases are not transferred into mitosis. In the kidney, however, our understanding of these processes is largely undescribed, and in the case of AKI, the activation of certain DNA repair
systems does not necessarily lead to a beneficial outcome to preserve or even restore renal function (13, 14).
Thyroid receptor interacting protein 13 (TRIP13) is an evolutionarily conserved family member of the
AAA+ ATPase enzymes (15, 16) and acts as an adapter protein with pleiotropic roles in pathways relevant
to meiotic/mitotic checkpoint control (17–22), DNA recombination (15, 16), and double-stranded DNA
repair (23). Insufficient production of Trip13 can increase cell cycle blockade at the G2/M phase (23) and
inefficiently repair double-stranded DNA breaks (16, 24, 25), which leads to the activation of apoptotic cell
death pathways in germline and somatic cells (16, 23–25). Moreover, TRIP13 directly activates DNA-dependent protein kinase catalytic subunit (DNA-PKcs), which is a primary enzyme involved in the non-homologous end joining (NHEJ) pathway of double-stranded DNA repair, to promote tumorigenesis (23).
1
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In the kidney, global Trip13Gt/Gt hypomorph mice exhibit prolonged tubular epithelial cell damage following bilateral ischemia/reperfusion injury, which is associated with increased DNA damage and activated
apoptotic signaling (26). To date, however, the role of TRIP13 to prevent tubular damage in other forms
of AKI, such as cisplatin nephrotoxicity, with respect to double-stranded breaks has yet to be studied.
In the present study, pharmacological inhibitors targeting double-stranded DNA repair pathways were
tested to determine any interference in the normal recovery of damaged renal tubules due to cisplatin.
To determine whether TRIP13 could modulate this process, a transgenic mouse model was generated to
conditionally overexpress Trip13 using the GGT1-Cre recombinase, since the main segment of cisplatin
nephrotoxicity is the proximal tubules. The Trip13 transgenic mice appeared normal with no evidence of
any abnormal renal morphology or function. In the face of AKI following cisplatin administration, the
Trip13-expressing kidneys were largely protected from injury with no apparent loss of renal function compared to their wild-type littermates. This study provides information about TRIP13 as a renal protectant
from nephrotoxic agents and suggests that this may be a new therapeutic target for AKI by circumventing
double-stranded DNA breaks during the recovery of the damaged renal tubules.

Results
Conditional Trip13 transgenic mouse model. A floxed stop codon strategy was employed to produce a conditional transgenic mouse model overexpressing Trip13. A DNA-targeting construct was designed and cloned
as shown in Figure 1A. In our approach, multiple stop codons were cloned between flanking loxP sites,
which were placed between the CAG promoter and the transgene cassette (Trip13-T2A-EGFP). This construct was injected for integration into the ROSA26 region into the zygotes, and litters were tested by
Southern blot analysis for proper DNA banding following genomic DNA restriction digest. Founder heterozygote Trip13Stop/+ males and females were interbred to obtain homozygous Trip13Stop/Stop mice. GGT-Cre
mice were used to breed with the heterozygous Trip13Stop/+ mice to generate GGT-Cre+/– Trip13Stop/+ mice.
Subsequently, the GGT-Cre+/– Trip13Stop/+ mice were bred with the homozygous Trip13Stop/Stop mice to produce littermates of homozygous Trip13Stop/Stop and GGT-Cre+/– Trip13Stop/Stop (Trip13ΔStop) mice for our study.
All mice were genotyped by PCR using specific primers shown in Table 1 and a representative ethidium
bromide–stained agarose gel showing different genotyped mouse pups (Figure 1B).
Phenotyping of the mice was performed by detecting FLAG-tagged TRIP13 and GFP by Western blot
analysis using protein lysates from harvested organs from female Trip13ΔStop mice (Figure 1C). FLAG and
GFP protein were clearly detected in the kidney lysates from Trip13ΔStop mice with undetectable expression
in the other organs tested, including duodenum, heart, lung, brain, and spleen. To determine the cell type(s)
expressing GFP in the kidneys, we performed immunohistology using 2 different detection methods. Fluorescent antibodies were tested on Trip13ΔStop mouse kidneys to determine whether GFP (shown in red) (Figure 1,
D, F, and H) would colocalize with either proximal tubule–specific lectin PVA-E (green brush border) (Figure
1, F and G) or collecting duct marker, DBA (Figure 1H). In the Trip13Stop/Stop mouse kidneys (Figure 1G), there
was minimal Alexa Fluor 555 intensity, demonstrating the lack of GFP expression without the presence of
Cre recombinase (Figure 1H). Similarly, minimal detection of GFP signal was detected in Trip13ΔStop mouse
kidneys in the absence of the primary antibody (negative control image in Figure 1E). Immunostaining was
absent in the lungs from both Trip13ΔStop (Figure 1I) and Trip13Stop/Stop (Figure 1J) mice, consistent with the lack
of GFP staining by Western blot analysis (Figure 1C). Similar results were obtained using DAB staining (data
not shown), showing the segment-specific expression of TRIP13 and GFP in our generated mouse model.
Overexpression of Trip13 in proximal tubules prevents the loss of renal function following cisplatin administration.
Cisplatin (15 mg/kg IP) was administered as a single dose into female Trip13Stop/Stop and Trip13ΔStop mice,
and tissues were harvested after 24 or 72 hours. Protein expression for GFP and FLAG-tagged TRIP13 was
clearly detectable by Western blot analysis using kidney lysates from Trip13ΔStop mice treated with either
vehicle or cisplatin (Figure 2A). No GFP or FLAG-tagged TRIP13 was detected in the Trip13Stop/Stop mouse
kidneys in either treatment group (Figure 2A).
In our initial study group, no significant difference in body weight was measured in both Trip13Stop/Stop
and Trip13ΔStop mice at 24 (n = 11) and 72 hours (n = 6) following vehicle treatment (data not shown). At
24 hours, there was a modest 5.4% decrease in body weight after which the body weight slightly increased
above the pretreatment weight by 7.4% at 72 hours. At 24 and 72 hours following cisplatin treatment, the
body weight in the Trip13Stop/Stop mice was progressively lower by 8.4% (n = 11) and 25.1% (n = 6), respectively, compared with pretreatment measurements, whereas the Trip13ΔStop mice had a lesser decrease in
JCI Insight 2021;6(22):e139092 https://doi.org/10.1172/jci.insight.139092
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Figure 1. Genomic targeting construct of Trip13 overexpression. (A) Targeting construct was designed for integration into the ROSA26 region, and the expression cassette was designed with the CAG promoter-floxed stop
codon-Trip13 cDNA-T2A-EGFP-polyA. 2A, protease cleavage site (Trip13 cDNA was FLAG tagged at the 3′ end); CAG,
CMV-IE enhancer/chicken β-actin/rabbit β-globin. (B) Genomic DNA isolated from mouse pups was PCR analyzed
using specific primers to differentiate wild-type, floxed stop, and Cre-containing mice. Wild-type (WT) = 453 bp;
floxed stop (flox) = 616 bp; and Cre = 400 bp. M = 1 kb ladder; lanes 1, 4, and 7 = F1/R1 primers (wild-type); 2, 5, and
8 = F2/R1 primers (floxed Trip13); and 3, 6, and 9 = GGT1-Cre primers (Cre); Trip13st/st, Trip13Stop/Stop. (C) Western blot
analysis of FLAG-tagged TRIP13 and GFP protein expression in harvested tissues from Trip13ΔStop mice. GAPDH was
shown as a loading control. K, kidney; Duo, duodenum; Hrt, heart; Br, brain; Lu, lungs; Spl, spleen. (D–H) Immunofluorescence was performed on FFPE Trip13Stop/Stop and Trip13ΔStop kidneys to detect GFP expression. GFP was detected
by Alexa Fluor 555 fluorescence (red color) in (G) Trip13Stop/Stop and (D, F, and H) Trip13ΔStop kidneys. E shows a negative
control kidney section incubated without primary GFP antibody (no primary). To determine proximal tubules (F and
G) or collecting ducts (H), Alexa Fluor 488 (green) fluorescence was detected using PVA-E (brush border of proximal
tubules) or DBA (collecting ducts). Nuclei were stained with DAPI (blue). Dashed lines in F indicate PVA-E–positive
tubules with minimal to undetectable expression of GFP, showing mosaicism of Cre expression. (I and J) Immunohistochemical staining for GFP in cisplatin-treated Trip13ΔStop and Trip13Stop/Stop mouse lungs. All DAB-stained sections
were counterstained with hematoxylin. Scale bar: 200 μm (D, E, I, and J), 100 μm (F–H). PVA-E, Phaseolus vulgaris
erthyroagglutinin; DBA, Dolicus biflorus agglutinin.

JCI Insight 2021;6(22):e139092 https://doi.org/10.1172/jci.insight.139092
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Table 1. PCR primers for genotyping
Primer name

F1
F2
R1
Cre forward
Cre reverse
GGT1-Cre (forward)
GGT1-Cre (reverse)

Sequence

5′-CACTTGCTCTCCCAAAGTCGCTC-3′
5′-AGATGTACTGCCAAGAGGAAAGTC-3′
5′-ATACTCCGAGGCGGATCACAA-3′
5′-GAACGCACTGATTTCGACCA-3′
5′-GCTAACCAGCGTTTTCGTTC-3′
5′-CCTGGAAAATGCTTCTGTCCG-3′
5′-CAGGGTGTTATAAGCAATCCC-3′

616 bp
453 bp
204 bp
400 bp

body weight (13.9%) after 72 hours. The changes in body weight were associated with the extent of AKI
by monitoring the blood chemistry for AKI markers, creatinine (Figure 2B) and neutrophil gelatinase-associated lipocalin (NGAL) (Figure 2C), and calculating the tubular damage (Figure 2, D–H).
Serum creatinine was significantly elevated in female Trip13Stop/Stop mice treated with cisplatin (1.95 ± 0.32
mg/dL; n = 6) compared with vehicle-treated littermates (0.11 ± 0.1 mg/dL; n = 6; Figure 2B). In the constitutive proximal tubule TRIP13-expressing (Trip13ΔStop; n = 8) mice following cisplatin administration, serum
creatinine values were only slightly elevated (0.16 ± 0.01 mg/dL; n = 8) compared with the vehicle-treated
mice (0.09 ± 0.01 mg/dL; n = 4) but significantly lower (P < 0.05) than those measured from the Trip13Stop/Stop
mice (n = 6). A similar trend was detected for serum NGAL levels, which rose to 240.0 ± 34.5 ng/L (n = 6)
in cisplatin-treated Trip13Stop/Stop mice but were markedly attenuated in the Trip13ΔStop mice (Figure 2C; n = 8).
Histological analyses of kidney sections were scored for tubular damage in all mouse groups following
treatment with a single dose of either vehicle or cisplatin (Figure 2D). Tubular damage was rare or completely nonexistent in vehicle-treated Trip13Stop/Stop mice kidneys after 24 (n = 5; Figure 2D) or 72 hours (n = 6;
(Figure 2, D and E) and Trip13ΔStop mice kidneys after 72 hours (n = 4) (Figure 2, D and G). In cisplatin-treated Trip13Stop/Stop mice, there was a significantly higher number of damaged tubules (40.1% ± 6.9%; n = 8;
Figure 2, D and F) as determined by the presence of dilated and cast-containing tubules compared with the
Trip13ΔStop mouse kidneys, which exhibited few damaged tubules (0.4% ± 0.1%; n = 8; Figure 2, D and H).
Cisplatin-dependent activation of DNA damage response pathway in mouse kidneys. Phosphorylated H2AX
(γ-H2AX; Ser139) was detected at 24 and 72 hours after cisplatin treatment, indicating DNA damage response
activation (Figure 3). Renal tubular epithelial cells positive for γ-H2AX were rarely detected in vehicle-treated
Trip13Stop/Stop mouse kidneys at both 24 (Figure 3, A and H) and 72 hours (Figure 3, E and H; 0.1%–0.2%; n
= 5–6/time point). At 24 hours, cisplatin-treated Trip13Stop/Stop mice had a high number (84.7% ± 5.6%; n = 5)
of the tubular epithelial cells positive for γ-H2AX (Figure 3, B and H). At 72 hours, the number of γ-H2AX–
positive tubular epithelial cells decreased from day 1 but remained elevated (56.3% ± 7.5%; n = 6) in the
cisplatin-treated Trip13Stop/Stop mice (Figure 3, D and H). In the Trip13ΔStop mice, there was a significantly lower
percentage of γ-H2AX–positive tubular epithelial cells (14.0% ± 4.0%; P < 0.05; n = 8) following treatment
with cisplatin after 72 hours (Figure 3, F and H). Rare activation of γ-H2AX was detected (0.2% ± 0.1%; n
= 4) in vehicle-treated Trip13ΔStop mouse kidneys (Figure 3, E and H). No γ-H2AX–positive tubular epithelial
cells were detected in the negative control section without the antibody (Figure 3G).
To determine whether other nucleotide modifications were observed following cisplatin administration,
we performed immunofluorescence on the kidney sections for 8-hydroxy-2′-deoxyguanosine (8-OHdG),
which is a common variant observed during oxidative stress–related damage. At 72 hours, 8-OHdG was
readily detected in the cisplatin-treated Trip13Stop/Stop mouse kidneys (Figure 3J), whereas no nuclei were
positive for 8-OHdG in the vehicle-treated mouse littermates (Figure 3I). In the Trip13ΔStop mice, there was
no detection of 8-OHdG in the vehicle-treated kidneys (Figure 3K) and considerably less intense fluorescence for 8-OHdG–positive nuclei following cisplatin treatment (Figure 3L).
The temporal activation of γ-H2AX following cisplatin treatment was associated with increased
G2/M blockade using phosphorylated (p-) histone H3 (Ser10; Figure 4, A–F), increased accumulation of
cyclin B1, and proapoptotic signaling by detecting cleaved caspase-3–positive tubular epithelial cells (Figure 4H). More specifically, the number of p–histone H3–positive (Ser10-positive) nuclei in tubular epithelia was significantly higher (P < 0.01) in cisplatin-treated Trip13Stop/Stop mice (18.9 ± 5.0 nuclei/image; n =
6; Figure 4, B and F) compared with both the vehicle-treated Trip13Stop/Stop (1.0 ± 0.3 nuclei/image; n = 6;
JCI Insight 2021;6(22):e139092 https://doi.org/10.1172/jci.insight.139092
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Figure 2. Trip13 overexpression in the proximal tubules provides protection from renal tubular epithelial cell damage
following cisplatin administration. Mice were injected with a single injection of vehicle (20% captisol in saline) or cisplatin (15 mg/kg IP), and kidneys and blood were harvested to detect markers of renal dysfunction. (A) Kidney samples from
homozygous floxed stop (Trip13Stop/Stop) and Trip13ΔStop mice were harvested from mice treated with either vehicle (-Cis; 20%
captisol) or cisplatin (+Cis; 15 mg/kg IP) after 72 hours following the initial injection. Western blot analysis was performed
using FLAG and GFP primary antibodies. GAPDH was used as a loading control. Arrows on the right side of the panel
indicate protein standard size. (B) Serum creatinine and (C) NGAL was measured in each mouse group. (D) Percentage of
tubular damage was determined in each group. (E–H) Representative histological images from (E and G) vehicle- or (F and
H) cisplatin-treated (15 mg/kg IP) Trip13Stop/Stop (E and F) and Trip13ΔStop (G and H) mice. Tubular epithelial cell damage was
scored as a percentage of total tubules counted. — = vehicle; + = cisplatin. *P < 0.05, ****P < 0.0001 between all other
groups using 1-way ANOVA with Tukey’s post hoc analysis. n = 4–8 animals per group. Scale bar: 200 μm (E–H).

Figure 4, A and F) and Trip13ΔStop (1.1 ± 0.6 nuclei/image; n = 4; Figure 4, C and F) mouse groups. In
the cisplatin-treated Trip13ΔStop mice, there was a significantly (P < 0.01) lower number of p–histone H3–
positive (Ser10-positive) cells (2.8 ± 1.5/image; n = 8; Figure 4, D and F) compared with vehicle-treated
littermates. No positive cells were detected in the negative control (no antibody) sections (Figure 4E).
JCI Insight 2021;6(22):e139092 https://doi.org/10.1172/jci.insight.139092
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Figure 3. Constitutive TRIP13 overexpression in the proximal tubules reduces activation of DNA damage following cisplatin administration.
Following cisplatin treatment (15 mg/kg IP), kidneys were harvested after 1 or 3 days for immunohistochemistry of (A–H) γ-H2AX (Ser139) and (I–L)
8-hydroxy-2′-deoxyguanosine (8-OHdG). After 24 (A and B) and 72 (C–F) hours following cisplatin administration, γ-H2AX (Ser139) was detected in (A–D)
Trip13Stop/Stop and (E and F) Trip13ΔStop mice and quantified by counting positive nuclei. Sections were counterstained with hematoxylin. Negative control
(no primary antibody) is shown (G) using sections from Trip13ΔStop mice treated with cisplatin at day 3. (H) Graphical analysis of γ-H2AX (Ser139) as a percentage of total nuclei. — = vehicle; + = cisplatin. ***P < 0.001, ****P < 0.0001 between the indicated groups using 1-way ANOVA with Tukey’s post hoc
analysis. (I–L) Immunofluorescence of 8-OHdG in kidney sections from vehicle- and cisplatin-treated Trip13Stop/Stop and Trip13ΔStop mice after day 3. Alexa
Fluor 555 (red) fluorescence was used to detect 8-OHdG, and Alexa Fluor 488 (green) fluorescence was used to detect proximal tubule lectin (PVA-E).
DAPI was used to detect nuclei (blue). Scale bar: 200 μm (A–G); 100 μm (I–L). n = 4–8 animals per group.

The increase in G2/M-positive tubular epithelial cells at 72 hours after cisplatin treatment was associated with a considerable increase in band intensity of cyclin B1 (Figure 4G) compared with vehicle treatment
in the Trip13Stop/Stop kidneys. In the Trip13ΔStop kidney lysates, endogenous levels of cyclin B1 were elevated
under normal conditions with no significant difference in the cyclin B1 accumulation in the cisplatin-treated Trip13ΔStop kidney lysates.
We found asignificantly higher percentage (4.5% ± 0.9%; n = 5; P < 0.0001) of cleaved caspase-3–
positive nuclei in cisplatin-treated Trip13Stop/Stop mice compared with the proximal tubular TRIP13-overexpressing Trip13ΔStop mouse kidneys (0.5% ± 0.2%; n = 7) (Figure 4H). Rare positive cells for cleaved
caspase-3 were evident in vehicle-treated Trip13Stop/Stop kidneys at both 24 (0.04% ± 0.02%; n = 5) and
72 hours (0.2% ± 0.1%; n = 6), or 24 hours following cisplatin treatment (0.08% ± 0.1%; n = 5; Figure
4H). Tubular epithelial cell proliferation was determined by staining with Ki67 and/or proliferating cell
nuclear antigen (PCNA) staining (Supplemental Figure 1; supplemental material available online with
this article; https://doi.org/10.1172/jci.insight.139092DS1). There was a significantly higher percentage of Ki67-positive nuclei by ~3.2-fold (P < 0.001) in the cisplatin-treated Trip13Stop/Stop mouse kidneys
(3.7% ± 0.5%; n = 4) compared with the vehicle-treated Trip13Stop/Stop group (1.2% ± 0.1%; n = 6). In the
vehicle-treated Trip13ΔStop mouse kidneys where Cre activation induced selective proximal tubular Trip13
expression, the percentage of Ki67-positive cells (1.1% ± 0.2%; n = 4) was not significantly different from
the control Cre-minus Trip13Stop/Stop mouse kidneys. Cisplatin treatment produced a small, but insignificant, increase in the Ki67-positive nuclei from the Trip13ΔStop mouse kidneys (1.6% ± 0.2%; n = 8). A
similar profile in PCNA-positive nuclei was observed in the same kidneys (Supplemental Figure 1).
In male mice, cisplatin at the same dose administered to females tended to have a slower and
less potent effect on body weight and kidney damage (Supplemental Figure 2). Serum creatinine was
JCI Insight 2021;6(22):e139092 https://doi.org/10.1172/jci.insight.139092
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Figure 4. Constitutive TRIP13 overexpression reduces apoptotic signaling and regulates intracellular signaling
pathways. (A–E) Representative images are shown for p–histone H3 (Ser10) in kidney sections obtained from vehicle- and cisplatin-treated Trip13Stop/Stop (A and B) and Trip13ΔStop (C and D) mice after day 3. Arrowheads are pointing at
individual or clusters of stained nuclei. (E) A negative control (no primary antibody) section was used from a cisplatin-treated Trip13Stop/Stop mouse. (F) Graphical analysis showing quantitative numbers of nuclei positive for p–histone
H3 (Ser10) in each image (3–4 images were counted per kidney section in each mouse). (G) Cyclin B1 bands were
shown following Western blot analysis using kidney lysates isolated from Trip13Stop/Stop and Trip13ΔStop mice treated
with either vehicle or cisplatin (15 mg/kg IP) after 72 hours. (H) Cleaved caspase-3–positive cells were counted relative to the total number of nuclei. — = vehicle; + = cisplatin (15 mg/kg IP). *P < 0.01 between all groups using 1-way
ANOVA with a Tukey’s post hoc analysis. Scale bar: 100 μm (A–D), 200 μm (E). n = 4–8 animals/group.

significantly lower (P < 0.001) at 0.8 ± 0.2 mg/dL (n = 8) in males compared with 1.95 mg/dL (n =
6) in females (Figure 2B) after 72 hours. Similarly, γ-H2AX (24.9% ± 1.9%; n = 8) was significantly
lower (P < 0.0001) by more than 50% in males compared with the females (56.3% ± 7.5%; Figure
3H), and this was associated with less tubular damage (29.4% ± 5.0%; n = 8) by approximately 25%
than females (Figure 2D).
Blockade of double-stranded DNA repair exacerbates cisplatin-dependent tubular damage. To evaluate whether the recovery of DNA damage associated with cisplatin nephrotoxicity required double-stranded DNA
break repair pathway activation, selective inhibitors to homologous recombination (mirin) or NHEJ
(NU7441) were administered to determine the effects on tubular damage and renal function.
Mirin is a selective inhibitor of Mre11-mediated homologous recombination (27), with relatively poor
solubility for in vivo studies. To improve the bioavailability of mirin, a nanoparticle formulation was prepared similarly to a prior study (28) and injected into the mice (50 mg/kg IP) immediately following the
injection of cisplatin (15 mg/kg IP). As a control, nanoparticles devoid of mirin were injected in a separate
group of mice. The chemical properties of the nanoparticles are shown in Supplemental Figure 3. As a
proof of concept, the nanoparticle formulation (50 μg) with indocyanine green (ICG) dye demonstrated
JCI Insight 2021;6(22):e139092 https://doi.org/10.1172/jci.insight.139092
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predominantly strong signal in intact mouse kidneys (Figure 5A) and following organ harvesting (Figure
5B) after 24 hours following IP administration. Figure 5C provides quantitative fluorescence in the isolated
organs of the injected mice after 24 hours, which showed that the kidney was about 4 times higher in fluorescence compared with the other organs, including the liver, lung, spleen, and heart.
Using the nanoparticle formulation in cisplatin-treated male Trip13Stop/Stop mice, the nanoparticle formulation containing mirin (NP-Mirin) exerted significantly increased (P < 0.05) tubular damage (Figure
5, D–G) and serum markers of AKI (creatinine and NGAL) (Figure 5, H and I) after 72 hours compared
with their control littermates treated with nanoparticles (NP-Ctrl). In this group, the lower creatinine levels
following cisplatin treatment on day 3 are probably attributed to a combination of the use of males rather
than females as well as the relatively high volume of NP solution (~0.7–1 mL) needed for injection into
the mice. Consistent with the increased physical damage and serum markers of AKI, γ-H2AX–positive
(Ser139-positive) cells were significantly higher (P < 0.01) in the NP-Mirin (40.9% ± 3.5%; n = 7) versus
NP-Ctrl group (17.5% ± 4.0% cells; n = 5) (Figure 5J). Overexpression of proximal tubular TRIP13 prevented the tubular damage even in the presence of mirin, and this was associated with lower serum creatinine (0.23 ± 0.04 mg/dL; P < 0.05), lower NGAL measurement (38.1 ± 8.5 ng/mL; n = 5; P < 0.05),
and fewer γ-H2AX–positive cells (20.0% ± 5.8%; n = 5; P < 0.05). No statistical difference was calculated
between the different groups for PCNA-positive nuclei regardless of the TRIP13 status (Figure 5K).
In addition, in the mice treated with both mirin and cisplatin, there was a significant ~2-fold increase
(P < 0.01; n = 4 mice/group) in DNA-PKcs mRNA levels compared with vehicle-treated mice (Figure 5L;
n = 4/group), which suggests a potential effect by the NHEJ pathway to compensate for DNA repair when
the homology directed repair pathway is partially to completely blocked.
To evaluate the role of the NHEJ pathway during cisplatin injury, a selective inhibitor to the
DNA-PKcs, NU7441 (20 mg/kg IP), was tested in a separate group of male Trip13Stop/Stop mice. The
experimental time was shortened compared with the other groups because of the 30% mortality rate
that was occurring within 48 hours after treatment with both cisplatin and NU7441 in the Trip13Stop/Stop
mice. All other non-NU7441-treated groups only exhibited observations of morbidity, but not mortality, prior to day 3 following cisplatin treatment.
Administration of NU7441 with vehicle solution for cisplatin (~0.1 mL) was injected at time 0 and at
24 hours, and the mouse kidneys were harvested after 48 hours. No adverse change in tubular architecture
(Figure 6, A–E) or renal function (0.09 ± 0.02 mg/dL; n = 7; Figure 6F) was observed. Following treatment
with cisplatin (15 mg/kg IP), the NU7441-treated Trip13Stop/Stop mice had significantly higher (P < 0.001)
serum creatinine (1.47 ± 0.49 mg/dL; n = 7) after 48 hours compared with cisplatin-treated littermates
without NU7441 (0.07 ± 0.01 mg/dL; n = 6). Tubular damage was consistent with the serum creatinine
values where the NU7441-treated mice exhibited significantly higher tubular damage (63.5% ± 16.1%; P
< 0.01; n = 7) compared with mice only treated with cisplatin and vehicle (9.8% ± 2.8%; n = 7) or vehicle
alone (n = 7) (Figure 6, A–E). Similarly, there was a tremendously higher number of γ-H2AX–positive
nuclei (Figure 6G) in the cisplatin-treated Trip13Stop/Stop with (36.5% ± 1.2%; n = 7) or without NU7441
(1.5% ± 0.4%; n = 7). Minimal activation of γ-H2AX was detected in control Trip13Stop/Stop mice treated
only with NU7441 (0.2 ± 0.1; n = 7). In the Trip13ΔStop mice (n = 4), cisplatin with NU7441 treatment did
not lead to any measurable change in serum creatinine (0.11 ± 0.02 mg/dL) (Figure 6F) or γ-H2AX–positive nuclei (1.8% ± 0.8%; n = 4) (Figure 6G) and only 9.5% ± 2.0% (n = 4) of tubular damage after 48 hours
(Figure 6, D and E). In cisplatin-treated Trip13Stop/Stop mice, treatment with NU7441 led to a small, but
significant (P < 0.05), reduction in Ki67-positive nuclei (1.0% ± 0.1%; n = 6) compared with vehicle-treated
mice (1.9% ± 0.3%; n = 6) (Figure 6H). No significant difference in Ki67-positive nuclei was calculated
between cisplatin-treated Trip13Stop/Stop (1.0% ± 0.1%; n = 7) and Trip13ΔStop (1.5% ± 0.1%; n = 4) mice treated with NU7441. In the absence of cisplatin, Trip13Stop/Stop mice treated only with NU7441 had a modest,
but significantly higher, number of Ki67-positive nuclei (P < 0.05; 1.8% ± 0.2%; n = 6).

Discussion
In the present study, constitutive de novo overexpression of TRIP13 in proximal tubules provided considerable protection to the kidney from acute nephrotoxic effects of cisplatin. Even though cisplatin or other
platinum-based compounds remain commonly prescribed to combat various types of cancer because of
their continued effectiveness, with constant daily use, these drugs can accumulate in the proximal tubules
and often produce deleterious acute effects in the kidney.
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Figure 5. Inhibition of double-strand break repair promotes tubular epithelial cell damage. (A and B) Nanoparticles
(50 μg) containing fluorescent ICG dye were injected into mice and monitored 24 hours later using IVIS system in (A)
living mice and (B) ex vivo excised organs. (C) Ex vivo organ fluorescence accumulation (n = 3 animals). K, kidney; Lu,
lung; Liv, liver; H, heart; Spl, spleen. Data represent mean ± SD. (D–G) Representative histological images from (D) vehicle- or (E and F) cisplatin-treated (15 mg/kg IP) Trip13Stop/Stop (D and E) and Trip13ΔStop (F) mice. (G) Tubular epithelial cell
damage was scored as a percentage of total tubules counted. Serum markers of AKI were monitored for (H) creatinine
and (I) NGAL after 72 hours following treatment with cisplatin (15 mg/kg IP) and NP-mirin or NP-Ctrl (50 mg/kg IP). (J)
γ-H2AX– (Ser139) and (K) PCNA-positive nuclei in kidney sections at 72 hours following cisplatin treatment with and
without mirin. NP without mirin (50 mg/kg IP) was used as the control solution. (L) Relative gene expression change
following treatment with cisplatin and/or mirin. Each of the respective groups was compared with mouse kidney values
obtained from control vehicle-treated Trip13Stop/Stop mice. (G–K) n = 5–7 mice/group; (L) n=4 mice/group. *P < 0.05, **P <
0.01 between all organs (C) or indicated groups (G, I, J, and L) or all groups (C) using 1-way ANOVA with Tukey’s post hoc
analysis. Significance for creatinine (H) was determined using Kruskal-Wallis nonparametric test with Dunn’s post hoc
analysis. Scale bar: 100 μm. + = administration of cisplatin or mirin; Cre - = Trip13Stop/Stop; Cre + = ΔStop.

One of the major consequences of cisplatin accumulation is the formation of reactive oxygen species
leading to genomic DNA modifications at the nucleotide level that can even produce lethal physical breaks
in the DNA. Consistent with this finding, we observed increased fluorescent nuclei for 8-OHdG, which is a
biomarker for oxidative damage (29) and can be an indicator for clustered DNA lesions that could indicate
double-stranded DNA breaks (DSBs) (30). Another early response to the DNA damage, including DSBs,
is the phosphorylation of a histone variant H2A (γ-H2AX) by distinct sensors (31), such as ataxia telangiectasia mutated (ATM) (32, 33), which is a primary mobilizer of the cellular response to DSBs. Due to the
pleiotropic effects induced by cisplatin on DNA, other sensors may be activated by crosstalk mechanisms
with ATM, including ataxia telangiectasia and Rad3 related (ATR) and DNA-PK, to control not only the
phosphorylation of H2AX (34), but also other downstream transducers (35). In general, a majority (about
two-thirds) of the cells that are destined to survive progress through the S phase of the cell cycle and exit
mitosis. This would lead to the formation of new and properly oriented epithelial cells (36, 37). To achieve
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Figure 6. Inhibition of DNA-PKcs accelerates AKI. NU7441 (20 mg/kg) was administered IP to Trip13Stop/Stop and
Trip13ΔStop mice that were euthanized prior to or at 48 hours to collect blood and kidneys. (A–D) Representative histological images from (A) vehicle- or (B–D) cisplatin-treated (15 mg/kg IP) Trip13Stop/Stop (A–C) and Trip13ΔStop (D) mice
coadministered with either vehicle (B) or NU7441 (20 mg/kg IP; A, C, and D). (E) Tubular epithelial cell damage was
scored as a percentage of total tubules. **P < 0.01 between all groups. (F) Serum markers of AKI were measured for
creatinine after 48 hours following treatment with cisplatin (15 mg/kg IP). *P < 0.05; **P < 0.01 between cisplatin- and
NU7441-treated mice. Positive nuclei for (G) γ-H2AX (Ser139) and (H) Ki-67 in kidney sections at 48 hours following cisplatin treatment with and without NU7441. *P < 0.05 between both genetic strains treated with cisplatin- and NU7441;
***P < 0.001 between all groups. One-way ANOVA with Tukey’s post hoc analysis was performed for each set of data
(E–H). n = 4–7 mice/group. Scale bar: 100 μm. ΔStop, Trip13ΔStop mice; Trip13St/St, Trip13Stop/Stop mice.

this level of recovery, the fate of the surviving tubular epithelial cells is determined by arresting the cell
cycle at distinct points, such as the intersection of G1/S and G2/M stage. This enables cells to make a
decision on whether to activate pathways to restore normal cellular function and become mitotically active
or undergo apoptotic cell death (38, 39). However, prolongation of G2/M arrest, which occurs in various
forms of AKI, can tilt the balance of the cellular fate toward cell death (40). This would inevitably slow or
produce incomplete recovery and lead to further deterioration in renal function (38, 39).
At present, the upstream signaling pathways involved with TRIP13 during DNA damage repair in
the mammalian system have yet to be fully described. In cultured tubular epithelia, cisplatin preferentially
activates the ATR/Chk2 signaling axis to promote renal cell apoptosis through TP53 activation (41). More
recently, proximal tubule knockout of ATR resulted in increased tubular damage, DNA damage, fibrosis,
and a loss of kidney function following kidney injury, which was associated with increased production of
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p53 and p21 (42). In oocytes with reduced endogenous production of TRIP13, partial activity of TP53
and its paralog, TAp63, was detected, leading to increased apoptotic cell death due to incomplete double-stranded DNA repair (25). A previous study from our lab also showed that injured tubular epithelial
cells could activate phosphorylated forms of TP53 (26), and this mechanism was linked to a direct interaction between TRIP13 and tetratricopeptide 5, which is a coactivator of p53 (26). Depending upon the type
and extent of DNA damage, TRIP13 may be a key regulator in controlling the pathways involved in DNA
repair and cell cycle progression, especially since hypomorph TRIP13 mice were unable to completely
repair their germline DNA, resulting in their fate being directed toward apoptosis (25). Further studies are
needed to explore how sensors and effectors normally associated with dSBs, namely ATM and DNA-PKcs,
are involved with TRIP13.
With that said, TRIP13 overexpression has been shown to promote a more aggressive state of growth in
somatic head and neck cancer cells by activating double-stranded DNA repair through the NHEJ pathway
(23). In that study, TRIP13 promoted DSB repair by directly binding and activating DNA-PKcs (23). In
general, NHEJ is considered the predominant pathway by which DSBs are repaired, particularly in lowly
mitotic cells (43). However, other pathways exist, such as homologous recombination, to ensure high-fidelity
repair following DNA damage. Emerging data that suggest TRIP13 acting as an AAA+ ATPase can remodel
protein conformations to actively switch the specific pathway involved in double-stranded DNA repair. For
example, Rev7-Shieldin complexes, which normally activate NHEJ pathways, can be dissociated by TRIP13
through a conformational change in Rev7 (44–46). This leads to a transition where the double-stranded DNA
repair is performed by homology-dependent recombination instead of NHEJ (44–46). A similar switch to
homologous recombination occurs when TRIP13 dissociates Rev3-Rev7 complexes, which normally activate
the translesion synthesis (TLS) pathway (44, 47). In our study, TRIP13 overexpression in the proximal tubules
may have been able to interchangeably swap DNA repair pathways following cisplatin injury in the presence
of selective pathway inhibitors, which led to the limited tubular damage and preserved kidney function.
In addition to DNA repair, TRIP13 is involved in the regulation of the mitotic checkpoint complex (MCC) (17–21, 48–51), which comprises a heterotetrameric protein complex that functions as
the primary inhibitor of the spindle assembly checkpoint (SAC). The SAC process maintains genome
stability by delaying anaphase until metaphase chromosomes are properly aligned with spindle attachment (52). In the case of cisplatin treatment, damaged kidney cells may be arrested at different phases
of the cell cycle, including G2/M, where the MCC would form and bind to the anaphase-promoting
complex or cyclosome (APC/C) to inhibit the SAC. To disassemble the MCC, TRIP13 performs a
series of mechanistic steps, which includes binding to p31comet and hydrolyzing ATP through its ATPase
activity, to facilitate a conformational change in a key MCC protein, mitotic arrest defective protein
2 (Mad2), from an active closed (C-Mad2) to an inactive open (O-Mad2) state (17–21, 48–51). This is
an important regulatory step as the formation of an active MCC is dependent upon the interaction of
C-Mad2 with CDC20, which is part of the MCC that binds to APC/C and prevents SAC activation. In
vitro experiments have shown that the TRIP13 is only capable of disassembling free MCC that is not
bound to the APC/C (51). This context-dependent effect by TRIP13 may be important during conditions of mitotic arrest, where TRIP13 levels were essential in determining the length of mitosis; i.e., in
the absence of TRIP13, mitotic length was considerably reduced whereas overexpression of TRIP13
rescued the mitotic length of the cell (18). Unperturbed mitosis is not dependent on the regulatory
actions of TRIP13 (18). Another factor that could affect both DNA repair and mitotic progression is
the potential competition in binding p31comet by either homodimer Rev7 or Mad2. The interaction by
p31comet with Rev7 instead of Mad2 could affect mitotic exit by dysregulating the control of the SAC by
MCC. Alternatively, p31comet sequestration of Rev7 from its normal binding partner, Rev3, could limit
the ability of the damaged DNA to recover using the TLS pathway following cisplatin exposure (53).
This may partially explain some of our observations where TRIP13 overexpression led to an increased
accumulation of cyclin B1 in normal kidneys. A constant pool of inactive O-Mad2 may have been produced from C-Mad2, which would have led to the dissociation of the non-APC/C-bound MCC into its
individual constituents. Upon exposure to an injurious stimuli, like cisplatin, the mitotic length may not
have been negatively affected or even blocked due to the absence of free MCC. This may have enabled
a higher number of injured cells to continue with their DNA repair, especially being potentiated by
TRIP13 overexpression. In the end, this may have directed the fate of the initially damaged cell toward
survival rather than death due to the more efficient repair of the damaged DNA.
JCI Insight 2021;6(22):e139092 https://doi.org/10.1172/jci.insight.139092

11

RESEARCH ARTICLE

In conclusion, our study demonstrated the production and testing of a floxed stop (LSL) mouse model that
can selectively induce Trip13 expression for in vivo investigation in the kidney, and potentially for other organs
in normal and injury states. Here, we present data that constitutive overexpression of TRIP13 in the proximal
tubules following cisplatin administration prevented the increased phosphorylation of H2AX in conjunction
with reduced blockade at the G2/M phase of the cell cycle. It would appear that normal tubular epithelia are
in a higher state of mitotic activity presumably due to TRIP13 overexpression in vivo. This may have promoted cell survival and limited apoptotic cell death from the nephrotoxic effects of cisplatin. Since TRIP13 was
detected in normal and AKI human kidney sections (Supplemental Figure 4) similar to our findings in mice
(26), TRIP13 or its associated binding proteins may become potential therapeutic targets to protect the kidney
from not only cisplatin nephrotoxicity but also possibly other forms of acute and chronic kidney disease.

Methods
Generation of conditional transgenic mice to express Trip13. Conditional Trip13-transgenic mice were generated
using a floxed stop strategy (Cyagen). The targeting construct was designed (from 5′ to 3′) as follows: a 5′
homology arm, a ubiquitously expressed CAG hybrid promoter, a loxP-flanked 3xSV40 poly(A) stop cassette, a 3X-FLAG epitope tag fused to Trip13, a T2A ribosomal skip cleavage peptide sequence, an EGFP
gene, a bovine growth hormone poly(A), and a 3′ homology arm. The mouse expressing γ-glutamyl transpeptidase–Cre recombinase mouse was bred into the homozygous lox-Stop-lox-Trip13-GFP (Trip13Stop/Stop)
mouse to produce the conditional GGT1-Cre+/– Trip13-GFP (Trip13ΔStop) mice. Mice were housed, bred,
and maintained in a specific pathogen–free animal facility at the University of Tennessee Health Science
Center. All experiments were approved by the IACUC (see Study approval). Mice were allowed ad libitum
access to food and water and maintained in a 12-hour light/12-hour dark cycle. Genotypes were confirmed by PCR amplification of genomic DNA isolated from toe or tail snip. The conditions for the floxed
primers (F1/R1 and F2/R2) were as follows: 94°C for 3 minutes; then 32 cycles of 94°C for 30 seconds,
66°C for 30 seconds, and 72°C for 12 seconds; and then a final extension of 72°C for 7 minutes. To detect
Cre recombinase, the PCR conditions for Cre for/Cre rev were as follows: 94°C for 3 minutes; then 32
cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 5 seconds; and then a final extension of
72°C for 7 minutes. The PCR product sizes were as follows: F1/R2 = 616 bp; F2/R2 = 453 bp; Cre for/
Cre rev = 204 bp. We used an initial pair of GGT1-Cre primers shown in Figure 1B, which were 400 bp in
size. PCR primer sequences are listed in Table 1.
Murine model of cisplatin-induced nephrotoxic AKI. Cisplatin nephrotoxic AKI was induced in randomly
distributed male and female Trip13Stop/Stop and GGT1-Cre+/– Trip13Stop/Stop mice (aged 8–12 weeks). Water was
removed from the mice for at least 12 hours prior to injecting the mice with a single IP dose of cisplatin (15
mg/kg) (Advanced ChemBlocks, catalog K12017) or vehicle (20% captisol dissolved in sterile saline). In some
mice, mirin (50 mg/kg) or NU7441 (20 mg/kg) was injected into the IP space either immediately or 6 hours
after the administration of cisplatin, respectively. Body weights were measured prior to the injection and every
24 hours for the duration of the experimental period. Blood was collected by submandibular bleeding after 24
and 72 hours following the initial injection to isolate plasma for measurement of creatinine by liquid chromatography–tandem mass spectrometry (Department of Biochemistry, University of Alabama at Birmingham)
and lipocalin-2 by ELISA kit (NGAL; Abcam ab119601). Prior to euthanasia, kidneys were removed and
placed either in neutral buffered formalin for paraffin embedding or on dry ice for protein isolation.
Chemicals and reagents for NP formulation. Poly(D, l-lactide-co-glycolide) (PLGA) (50:50 lactide-glycolide ratio,
MW: 31,000–50,000, ester terminated) was purchased from Birmingham Polymers. Poly(vinyl alcohol) (PVA)
(363138, MW: 30,000–70,000), poly(l-lysine) (PLL) (MW: 30,000–70,000), Pluronic F-68 (P1300, MW: 8350),
and coumarin 6 (442631, 98%) were purchased from MilliporeSigma and used without further purification.
Preparation and characterization of PLGA-mirin NPs. PLGA NP formulation with mirin and control
PLGA NPs were prepared by nanoprecipitation technique (54). Briefly, PLGA (90 mg) with or without
mirin (50 mg) was dissolved in 10 mL of acetone to achieve a uniform solution; 2% PVA-aqueous solution was prepared in cold water, kept under stirring until it dissolved. To this freshly prepared PVA solution, PLGA-mirin or PLGA-alone hydrophobic solution was added dropwise and stirred on a magnetic
stir plate at 1000 rpm. The next day, after the acetone evaporated, 10 mg of PLL and 10 mg of Pluronic
F-68 were dissolved in water, added to the NP suspension, and stirred for at least 6–8 hours. The formulation was stored at 4°C until further use. Similarly, ICG-PLGA NPs were prepared by replacing mirin
for mouse imaging studies (55, 56).
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The particle size (nm) and zeta potential (mV) of prepared PLGA NPs and PLGA-mirin NPs were
acquired by dynamic light scattering principle using Zetasizer (Nano ZS, Malvern Instruments) (57). The
particle size measurements were performed at 25°C using 50 μL of freshly prepared PLGA NPs diluted
in 1 mL of ultrapure water and probe sonicated using VirSonic Ultrasonic Cell Disrupter 100 (The VirTis
Company) for 30 seconds. Particle size of formulations was measured in filtered water/PBS/DMEM to
confirm stability of the particle in a physiologically relevant environment. The measurement was reported
from 3 runs (~2 minutes each run). The zeta potential of NPs (50 μL of nanoformulation in 1 mL of 1×
PBS) was measured in triplicate (each reading = 30 runs) by laser Doppler microelectrophoresis technique.
Fourier transform infrared (FTIR) spectral data of blank NPs and mirin-loaded PLGA NP formulation
were obtained from lyophilized solid powders (Labconco Freeze Dry System,–48°C, 133 × 10–3 mbar) (58).
FTIR spectra of samples were obtained between 4000 and 650 per cm on the Universal ATR sampling
Accessory plate using a Spectrum 100 FTIR spectrophotometer.
Tissue distribution of NPs following IP injection. Athymic male nude mice, 8 weeks old (Jackson Laboratory), were used, and the experiments were conducted in accordance with the IACUC at University of Tennessee Health Science Center (UTHSC). For this experiment, each of the 3 mice were injected into the IP
space with PLGA-NPs containing ICG dye (50 μg). After 24 hours, mice were anesthetized with isoflurane
and imaged using with a coupled device camera in IVIS XRMS Imaging System (Caliper Life Sciences)
(55, 56). To confirm the fluorescence intensity from each organ, the mice were euthanized to harvest various organs for arrangement on a Petri dish. Both in vivo and ex vivo imaging were performed to detect
fluorescence levels emitted by the PLGA-NP-ICG at an excitation filter of 690 nm for 5000 ms. The data
were presented in photons per second per square centimeter per steradian (p/s/cm2/sr).
Histopathology. Paraffin-embedded sections (4 μm) were deparaffinized in xylene and rehydrated in
increasing ethanol percentages to prepare for staining with hematoxylin and eosin. The kidney sections were
deidentified and scored by a blinded nephrologist with expertise in rodent models of AKI to assess tubular
injury. The criteria for damaged tubules included the identification of flattened epithelia, tubular dilation, and
cast formation as previously described in our lab (23, 25, 26, 59–61). The injured tubules were calculated as a
percentage of the total number of tubules counted in 3–5 different sections from every animal in each group.
Immunofluorescent histochemistry in kidney sections. Immunohistochemistry was performed on deparaffinized kidney sections (4 μm). Antigen retrieval was performed by heating for 45–50 minutes, and slides
were washed in peroxidase blocking solution for 15 minutes. For sections stained with 8-OH-dG, RNase A
(Invitrogen, Thermo Fisher Scientific) (20 μg/mL) was added for 60 minutes at 37°C. The tissue sections
were washed in 1× TBS with 0.08% Triton X-100 for 10 minutes and blocked in 2.5% normal donkey
serum for 60 minutes. Monoclonal GFP antibody (B-2; 1:100-1:200; Santa Cruz Biotechnology catalog
sc-9996) or 8-OHdG (1:20 dilution; catalog ab48508; Abcam), and polyclonal Ki67 (catalog 15580, 1:200;
Abcam), were incubated on the tissues overnight at 4°C. The tissues were washed 3 times in 1× TBS and
the secondary donkey anti–mouse IgG conjugated with Alexa Fluor 555 (1:250 dilution; catalog A-31570;
Invitrogen, Thermo Fisher Scientific). To determine specific segments of the nephron, biotinylated PVA-E
(1:500 dilution; proximal tubules; Vector Laboratories) or DBA (1:500; collecting ducts) lectin was incubated onto the sections for 30 minutes at 25°C, then with streptavidin-linked IgG with Alexa Fluor 488 (1:500
dilution; Invitrogen, Thermo Fisher Scientific, catalog S11223) for 30 minutes. The sections were mounted
with DAPI and imaged on the EVOS light microscope at 20× to 40× original magnification.
Immunohistochemistry using DAB as the substrate. Immunohistochemistry was performed on deparaffinized kidney sections (4 μm) using a slightly modified protocol from that previously described (26, 61, 62). In
brief, antigen retrieval was performed by heating for 30–50 minutes, incubating in peroxidase blocking solution to minimize endogenous peroxidase activity, and tissue permeabilizing in 1× Tris buffer saline containing 0.08% Triton X-100. The following primary monoclonal mouse antibody against PCNA (catalog
2586; 1:250; Cell Signaling Technology), and primary polyclonal rabbit antibodies against phospho-H2AX
(Ser139) (catalog 9718; 1:250, Cell Signaling Technology), phospho–histone H3 (Ser10; catalog 9701;
1:250; Cell Signaling Technology), cleaved caspase-3 (catalog 9661, 1:200; Cell Signaling Technology),
and Ki67 (catalog 15580, 1:200; Abcam) were used on the kidney sections. Secondary goat anti–rabbit IgG
(Invitrogen, Thermo Fisher Scientific; 1:250) and goat anti–mouse IgG conjugated to horseradish peroxidase (1:250; Cell Signaling Technology catalog 7076) were used and detected using DAB (MilliporeSigma).
To determine the localization of GFP to the proximal tubules, PVA-E (Vector Laboratories B-1125) lectin
conjugated to biotin was used (1:250). Sections were counterstained with hematoxylin. Pictures were taken
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with an EVOS light microscope at 20× to 40× original magnification. The percentage of positive nuclei for
the target proteins was calculated as a total number of nuclei.
Western blot analysis. Protein lysates were isolated from the harvested mouse organs by homogenization in 1× RIPA buffer containing protease and phosphatase inhibitors (Thermo Fisher Scientific)
followed by differential centrifugation as previously described (26, 61, 62). Western blot analysis was
performed using a 4%–12% SDS-PAGE gradient gel, then transferred to either PVDF or nitrocellular
membranes, and bands were detected by chemiluminescence (GE, now Cytiva) using Bio-Rad ChemiDoc MP imaging system. Antibodies used in this protocol were as follows: GFP (catalog sc-9996; Santa
Cruz Biotechnology), FLAG (catalog A8592-1MG; MilliporeSigma), Mad2L1 (catalog 4636, 1:1000;
Cell Signaling Technology), p31comet (Abcam catalog 150363), TRIP13 (Abcam catalog ab128153), p-p53
(Ser15) (Cell Signaling Technology catalog 9286), and cyclin B1 (Cell Signaling Technology catalog
4135). As a loading control, GAPDH (1:1500; Cell Signaling Technology) was used. All the antibodies
were tested using proteins transferred onto PVDF membranes except for cyclin B1 (nitrocellulose).
Quantitative reverse transcription PCR analysis of gene expression. Total RNA was extracted using an mRNA
isolation kit (Invitrogen, Thermo Fisher Scientific), and cDNA was synthesized using SuperScript III
cDNA synthesis kit. Using 1 μg of each RNA, quantitative PCR analyses were carried out in duplicate samples using TaqMan probes, the TaqMan Universal PCR Master Mix (Applied Biosystems, Thermo Fisher
Scientific), and a Step One Plus Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific).
The primer set targeting 18S RNA and DNA-PKcs (Mn01342966_g1) was tested on our samples. Relative
gene expression quantification was calculated according to the comparative threshold cycle method using
18S rRNA as the endogenous control (63). As a negative control, no template conditions were performed
for each primer set to ensure the absence of any spurious DNA amplification by the primer combinations.
Statistics. All data are shown as mean ± SEM. The data were tested for normality with the Kolmogorov-Smirnov test using GraphPad Prism 6.0. Normally distributed data were tested with 1-way ANOVA,
and subsequent post hoc analysis was performed by Tukey’s multiple-comparison test. Non-normally
distributed data were tested with the Kruskal-Wallis test for significance among multiple groups followed
by Dunn’s multiple-comparison test. P ≤ 0.05 was considered significant.
Study approval. Deidentified human kidney sections previously scored as normal or AKI were
obtained from the University of Alabama at Birmingham using IRB approval X130124002. All animal
protocols (AUA 17-032, 18-097, and 19-0102) were approved by the UTHSC IACUC prior to the start
of any of the experiments.
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